Multiple myeloma is a hematological cancer type. For its treatment, Bortezomib has been
widely used. However, drug resistance to this effective chemotherapeutic has been …

The development of single-cell subclones, which can rapidly switch from dormant to
dominant subclones, occur in the natural pathophysiology of multiple myeloma (MM) but is …

With the development of modern medicine, the research methods of occurrence,
development and treatment of orthopedic diseases are developing rapidly. The …

Simple Summary New treatments have made a big difference in helping people with
multiple myeloma (MM) live longer. In fact, survival rates have almost doubled compared …

This study explores the role of digital financial inclusion in mitigating poverty and bolstering
economic growth, with a special focus on developing nations during the COVID-19 era …

The clinical benefits of the MammaPrint® signature for breast cancer is well documented;
however, how these genes are related to cell cycle perturbation have not been well …

Cancer cells sharing stem cell properties are called “cancer stem cells”(CSCs). CSCs have
distinct metabolic properties, are intrinsically drug resistant evading chemotherapies, are …

Multiple Myeloma (MM), a prevalent hematological cancer, remains a challenge due to its
intricate nature and variable outcomes. Cytogenetics, the study of chromosome structure …

Studying on subclonal evolution of cancer stem cells can help illustrate how the immune
system recognizes tumor cells, leading to subclonal treatment by immune-based therapies …

Corrigendum to: Microfluidic enrichment of plasma cells improves treatment of multiple
myeloma - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …